Is Glenmark Pharmaceuticals Ltd a good quality company?

MoneyWorks4Me analysed the past 10-year performance of Glenmark Pharmaceuticals Ltd and arrived at the following conclusion.

Is the current market price of Glenmark Pharmaceuticals Ltd a good price to buy it?

The 5-year analysis of Glenmark Pharmaceuticals Ltd's performance infers.

What is Glenmark Pharmaceuticals Ltd share price return in the past 10 years?

We analysed the performance of Glenmark Pharmaceuticals Ltd share prices over the last 10 years. Here is what we found out:

What is a Financial Track Record? How to read this chart in order to understand the data present here?

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance

Difference between Standalone Basis and Consolidated basis? Which method is preferred for Glenmark Pharmaceuticals Ltd

Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.

What is CAGR? What does CAGR table indicate for Glenmark Pharmaceuticals Ltd?

Compounded average growth rate (CAGR) measures the average annual growth rate compounded year-on-year over a period of time.

Glenmark Pharmaceuticals informs about media release

Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 532296 | NSE: GLENMARK

23 Aug 2019

Evaluate

Glenmark Pharmaceuticals has informed about media release titled: ‘Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)’.

The above information is a part of company’s filings submitted to BSE.

Related Glenmark Pharmaceuticals Ltd. Links:

Analysis

Reports

News

Stock Price

Sector News